Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
Add more filters











Publication year range
1.
Behav Brain Res ; 336: 145-150, 2018 01 15.
Article in English | MEDLINE | ID: mdl-28842271

ABSTRACT

The sensorimotor cortex and the striatum are interconnected by the corticostriatal pathway, suggesting that cortical injury alters the striatal function that is associated with skilled movements and motor learning, which are functions that may be modulated by dopamine (DA). In this study, we explored motor coordination and balance in order to investigate whether the activation of D1 receptors (D1Rs) modulates functional recovery after cortical injury. The results of the beam-walking test showed motor deficit in the injured group at 24, 48 and 96h post-injury, and the recovery time was observed at 192h after cortical injury. In the sham and injured rats, systemic administration of the D1R antagonist SCH-23390 (1mg/kg) alone at 24, 48, 96 and 192h significantly (P<0.01) increased the motor deficit, while administration of the D1R agonist SKF-38393 alone (2, 3 and 4mg/kg) at 24, 48, 96 and 192h post-injury did not produce a significant difference; however, the co-administration of SKF-38393 and SCH-23390 prevented the antagonist-induced increase in the motor deficit. The cortical+striatal injury showed significantly increased the motor deficit at 24, 48, 96 and 192h post-injury (P<0.01) but did not show recovery at 192h. In conclusion, the administration of the D1R agonist did not accelerate the motor recovery, but the activation of D1Rs maintained motor coordination, confirming that an intact striatum may be necessary for achieving recovery.


Subject(s)
Receptors, Dopamine D1/metabolism , Receptors, Dopamine D1/physiology , Sensorimotor Cortex/physiology , 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine/metabolism , 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine/pharmacology , Animals , Benzazepines/metabolism , Benzazepines/pharmacology , Brain Injuries, Traumatic/metabolism , Brain Injuries, Traumatic/physiopathology , Corpus Striatum/metabolism , Disease Models, Animal , Dopamine/metabolism , Dopamine Antagonists/pharmacology , Male , Motor Cortex/physiopathology , Neostriatum/metabolism , Rats , Rats, Wistar , Receptors, Dopamine D1/agonists , Receptors, Dopamine D2/metabolism , Sensorimotor Cortex/metabolism
2.
Neurochem Int ; 50(1): 211-8, 2007 Jan.
Article in English | MEDLINE | ID: mdl-17014930

ABSTRACT

Dopamine is the main catecholamine found in the chick retina whereas norepinephrine is only found in trace amounts. We compared the effectiveness of dopamine and norepinephrine in promoting cyclic AMP accumulation in retinas at embryonic day 13 (E13) and from post-hatched chicken (P15). Dopamine (EC(50)=10microM) and norepinephrine (EC(50)=30microM), but not the beta(1)-adrenergic agonist isoproterenol, stimulated over seven-fold the production of cyclic AMP in E13 retina. The cyclic AMP accumulation induced by both catecholamines in embryonic tissue was entirely blocked by 2microM SCH23390, a D(1) receptor antagonist, but not by alprenolol (beta-adrenoceptor antagonist). In P15 retinas, 100microM isoproterenol stimulated five-fold the accumulation of cAMP. This effect was blocked by propanolol (10microM), but not by 2microM SCH23390. Embryonic and adult retina display beta(1) adrenergic receptor mRNA as detected by RT-PCR, but the beta(1) adrenergic receptor protein was detected only in post-hatched tissue. We conclude that norepinephrine cross-reacts with D(1) dopaminergic receptor with affinity similar to that of dopamine in the embryonic retina. In the mature retina, however, D(1) receptors become restricted to activation by dopamine. Moreover, as opposed to the embryonic tissue, norepinephrine seems to stimulate cAMP accumulation via beta(1)-like adrenergic receptors in the mature tissue.


Subject(s)
Dopamine Agonists/pharmacology , Norepinephrine/pharmacology , Receptors, Adrenergic, beta-1/metabolism , Receptors, Dopamine D1/agonists , Retina/drug effects , Animals , Benzazepines/metabolism , Cells, Cultured , Chick Embryo , Radioligand Assay , Retina/cytology , Retina/embryology
3.
Cell Mol Neurobiol ; 26(1): 1-15, 2006 Feb.
Article in English | MEDLINE | ID: mdl-16633898

ABSTRACT

This work was designed to study the changes produced by cocaine-induced seizures and lethality on dopaminergic D(1)- and D(2)-like receptors, muscarinic M(1)-like binding sites, as well as acetylcholinesterase activity in mice prefrontal cortex (PFC) and striatum (ST). Binding assays were performed in brain homogenates from the PFC and ST and ligands used were [(3)H]-N-methylscopolamine, [(3)H]-NMS (in the presence of carbachol), [(3)H]-SCH 23390 and [(3)H]-spiroperidol (in presence of mianserin), for muscarinic (M(1)-like), D(1)- and D(2)-like receptors, respectively. Brain acetylcholinesterase (AChE) activity was also determined in these brain areas. Cocaine-induced SE decreased [(3)H]-SCH 23390 binding in both ST and PFC areas. A decrease in [(3)H]-NMS binding and an increase in [(3)H]-spiroperidol binding in PFC was also observed. Cocaine-induced lethality increased [(3)H]-spiroperidol binding in both areas and decreased [(3)H]-NMS binding only in PFC, while no difference was seen in [(3)H]-SCH 23390 binding. Neither SE, nor lethality altered [(3)H]-NMS binding in ST. AChE activity increased after SE in ST while after death the increase occurred in both PFC and ST. In conclusion, cocaine-induced SE and lethality produces differential changes in brain cholinergic and dopaminergic receptors, depending on the brain area studied suggesting an extensive and complex involvement of these with cocaine toxicity in central nervous system.


Subject(s)
Brain/drug effects , Cocaine , Dopamine Uptake Inhibitors , Receptor, Muscarinic M1/metabolism , Receptors, Dopamine D1/metabolism , Receptors, Dopamine D2/metabolism , Status Epilepticus/chemically induced , Acetylcholinesterase/metabolism , Animals , Benzazepines/metabolism , Binding Sites , Brain/metabolism , Cocaine/pharmacology , Cocaine/toxicity , Dopamine Antagonists/metabolism , Dopamine Uptake Inhibitors/pharmacology , Dopamine Uptake Inhibitors/toxicity , Humans , Male , Mice , N-Methylscopolamine/metabolism , Parasympatholytics/metabolism , Spiperone/metabolism
4.
Brain Res ; 1038(2): 141-9, 2005 Mar 21.
Article in English | MEDLINE | ID: mdl-15757630

ABSTRACT

Glia represents the most numerous group of nervous system cells and CNS development and function depend on glial cells. We developed a purified Muller glia culture to investigate the expression of several neurotransmitter markers on these cells, such as dopaminergic, cholinergic, GABAergic and peptidergic receptors or enzymes, based on functional assays measuring second messenger levels or Western blot for specific proteins. Purified Muller cell culture was obtained from 8-day-old (E8) embryonic chick. Glial cells cultured for 15 days (E8C15) expressed D1A and D1B receptors mRNAs, but not D1D, as detected by RT-PCR. The binding of [3H]-SCH 23390 revealed an amount of expressed receptors around 40 fmol/mg protein. Dopamine (100 microM), PACAP (50 nM) and forskolin (10 microM) induced a 50-, 30- and 40-fold cAMP accumulation on glial cells, respectively, but not ip3 production. The dopamine-promoted cAMP accumulation was blocked by 2 microM SCH 23390. Carbachol stimulated a 3-fold ip3 accumulation. Western blot analysis also revealed the expression of tyrosine hydroxylase, L-dopa decarboxylase, PAC1 receptor, GAD67 and beta2-nicotinic receptor subunit by these cells. These results indicate that several components of neurotransmitter signaling and metabolism are found in cultured Muller cells.


Subject(s)
Neuroglia/metabolism , Neurotransmitter Agents/metabolism , Receptors, Neurotransmitter/metabolism , Animals , Benzazepines/metabolism , Biomarkers , Blotting, Western , Cells, Cultured , Chick Embryo , Colforsin/pharmacology , Cyclic AMP/metabolism , Dopamine/metabolism , Dopamine/pharmacology , Dopamine Antagonists/metabolism , Inositol 1,4,5-Trisphosphate/metabolism , Nerve Growth Factors/pharmacology , Neuroglia/enzymology , Neurons/metabolism , Neuropeptides/pharmacology , Neurotransmitter Agents/pharmacology , Pituitary Adenylate Cyclase-Activating Polypeptide , Raclopride/metabolism , Receptors, Dopamine D1/genetics , Receptors, Dopamine D1/metabolism , Retina/cytology , Retina/metabolism , Reverse Transcriptase Polymerase Chain Reaction
5.
Life Sci ; 76(19): 2193-202, 2005 Mar 25.
Article in English | MEDLINE | ID: mdl-15733934

ABSTRACT

The present work studied in vivo neuroprotective effects of n-acetylserotonin (NAS), the immediate precursor of melatonin, on the dopaminergic system, in rats lesioned with the unilateral intrastriatal injection of the neurotoxin 6-hydroxydopamine (6-OHDA). Two weeks after the lesion, the dopamine receptor agonist, apomorphine, produced rotational asymmetry, and the NAS treatment significantly reduced the motor deficit following the apomorphine challenge. The apomorphine-induced rotational behavior was blocked by 84, 86 and 53% after NAS, at doses of 2, 5 and 10 mg/kg, i.p., respectively. The injection of 6-OHDA significantly decreased DA, DOPAC and HVA levels in the rat striatum. In contrast, the NAS (2, 5 and 10 mg/kg, i.p., daily for 7 days) treatment partially reversed the decreases caused by 6-OHDA, and the neurotransmitter levels were brought to approximately 50% of that observed in the contralateral sides. NAS was more efficient at the smaller doses. NAS (5 mg/kg) produced an up-regulation of D1 (37%) and D2 (37%) receptors associated with a decrease in Kd values.


Subject(s)
Neurotoxicity Syndromes/prevention & control , Oxidopamine/antagonists & inhibitors , Oxidopamine/toxicity , Serotonin/analogs & derivatives , Serotonin/pharmacology , Sympatholytics/antagonists & inhibitors , Sympatholytics/toxicity , Animals , Apomorphine/pharmacology , Benzazepines/metabolism , Binding, Competitive/drug effects , Biogenic Monoamines/metabolism , Cell Count , Dopamine/metabolism , Dopamine Agonists/pharmacology , Dopamine Antagonists/metabolism , Male , Microinjections , Neostriatum/drug effects , Neostriatum/metabolism , Neostriatum/pathology , Neurons/drug effects , Neurons/pathology , Neurotoxicity Syndromes/pathology , Oxidopamine/administration & dosage , Rats , Rats, Wistar , Receptors, Dopamine D1/drug effects , Receptors, Dopamine D2/drug effects , Rotation , Serotonin/metabolism , Stereotyped Behavior/drug effects , Sympatholytics/administration & dosage
6.
Neurochem Res ; 26(5): 533-7, 2001 May.
Article in English | MEDLINE | ID: mdl-11513481

ABSTRACT

We have previously demonstrated that neuropeptide-EI, at high doses, stimulates the production of cAMP, in caudate putamen, through the activation of adenylate cyclase coupled to specific D1 receptors. The aim of the present work was to find evidences for a probable interaction between this neuropeptide and the dopamine D1 receptor in the mammalian central nervous system. The present data show that neuropeptide-EI, at high concentrations, affected both the maximum binding and the apparent affinity of [n-methyl-3H] (R)-(+)-8 chloro-2,3,4,5-tetrahydro-3-methyl-5-phenyl-1H-3-benzazepin-7-ol hemimaleate to the dopamine D1 receptor in a concentration-dependent manner.


Subject(s)
Benzazepines/metabolism , Corpus Striatum/metabolism , Dopamine Antagonists/metabolism , Oligopeptides/pharmacology , Receptors, Dopamine D1/metabolism , Animals , Binding, Competitive/drug effects , Male , Membranes/metabolism , Osmolar Concentration , Rats , Rats, Wistar , Synaptosomes/metabolism , Tritium
7.
Eur J Pharmacol ; 363(2-3): 211-5, 1998 Dec 18.
Article in English | MEDLINE | ID: mdl-9881592

ABSTRACT

We have previously demonstrated that the simultaneous presence of alpha-melanocyte stimulating hormone (alpha-MSH) and dopamine resulted in a reduction in cyclic AMP (cAMP) levels in slices containing caudate putamen and accumbens nuclei as compared to those treated only with dopamine or alpha-MSH. This study was carried out to explore if the interaction between alpha-MSH and dopamine could be explained on the basis of a direct interaction between alpha-MSH and the dopamine D1 receptor. Saturation curves for [n-methyl-3 H](R)-(+)-8 chloro-2,3,4,5-tetrahydro-3-methyl-5-phenyl-1 H-3-benzazepin-7-o] hemimaleate ([3H]SCH 23390) binding in the presence of increasing concentrations of alpha-MSH were performed. Nonlinear regression in the presence of alpha-MSH revealed an increased dissociation constant (Kd). The binding capacity (Bmax) was not affected by the peptide. These data suggest an apparent competitive interaction between alpha-MSH and [3H]SCH 23390 in striatal membranes on the dopamine D1 receptor; (Ki = 1.2 X 10(-7) M). The present data show that alpha-MSH could interact with the dopamine D1 receptor modulating allosterically the affinity of [3H]SCH 23390 for the receptor or by causing a change in the lipid environment of the dopamine receptor, resulting in an inhibition of the ligand binding to it.


Subject(s)
Benzazepines/metabolism , Corpus Striatum/metabolism , Dopamine Antagonists/pharmacology , Receptors, Dopamine D1/metabolism , alpha-MSH/pharmacology , Animals , Benzazepines/pharmacology , Binding, Competitive/drug effects , Cell Membrane/drug effects , Cell Membrane/metabolism , Corpus Striatum/drug effects , Dopamine/metabolism , In Vitro Techniques , Male , Rats , Rats, Wistar , Receptors, Dopamine D1/antagonists & inhibitors , Synaptosomes/drug effects , Synaptosomes/metabolism , Tritium
8.
Neurosci Lett ; 167(1-2): 195-7, 1994 Feb 14.
Article in English | MEDLINE | ID: mdl-8177524

ABSTRACT

Ligand binding to dopamine uptake sites, D1 and D2 dopamine receptors was measured autoradiographically in brain sections of mice exposed to intermittent hypobaric hypoxia (450 Torr; 4,300 m) for 14 days and compared to sea level controls. Desipramine-insensitive [3H]mazindol, [3H]SCH23390 and [3H]YM-09151-2 were used respectively for the labeling of the three binding sites. After 14 days, the striatum of hypoxic mice showed a significant 21% increase in dopamine uptake sites, one of the loci of action of cocaine. A similar (28%) but non-significant increase was found in the ventral tegmental area. No changes were seen in the activities of D1 or D2 receptors in several areas examined including the substantia nigra and the striatum.


Subject(s)
Corpus Striatum/metabolism , Dopamine/pharmacokinetics , Hypoxia/metabolism , Animals , Autoradiography , Benzamides/metabolism , Benzazepines/metabolism , Binding Sites , Desipramine/pharmacology , Dopamine D2 Receptor Antagonists , Male , Mazindol/metabolism , Mice , Mice, Inbred BALB C , Receptors, Dopamine D1/metabolism , Receptors, Dopamine D2/metabolism , Time Factors
9.
Brain Res Bull ; 34(5): 453-6, 1994.
Article in English | MEDLINE | ID: mdl-8082038

ABSTRACT

Previous work had shown that paradoxical sleep deprivation (PSD) results in potentiation of several apomorphine-induced behaviors, leading to the suggestion that PSD induces an upregulation of brain dopamine receptors. In this study, quantitative receptor autoradiography was used to verify whether PSD does, in fact, induce alterations in D1 or D2 receptor binding, and to investigate the regional brain specificity of such effects. After 96 h of PSD, [3H]SCH-23390 binding to D1 receptors was examined in 30 different brain areas of 10 experimental and 10 cage control rats. [3H]Spiperone was used to label D2 sites in adjacent tissue sections. Results revealed a 39% increase in [3H]SCH-23390 binding in the entorhinal cortex of PSD rats (p < 0.05), but no other changes in any of the remaining 29 brain areas examined. In contrast, [3H]spiperone binding was significantly elevated in the n. accumbens (+45%) and in all subregions of the caudate-putamen (range: +13% to +23%). These results, thus, provide evidence that PSD increases D2 but not D1 receptor binding in brain. The present results also suggest that upregulated D2 receptors can account for the previously reported changes in apomorphine-induced behaviors after PSD.


Subject(s)
Brain/metabolism , Receptors, Dopamine D1/metabolism , Receptors, Dopamine D2/metabolism , Sleep Deprivation/physiology , Sleep, REM , Animals , Autoradiography , Benzazepines/metabolism , Male , Rats , Rats, Wistar , Spiperone/metabolism , Tissue Distribution
10.
Brain Res Dev Brain Res ; 69(2): 199-205, 1992 Oct 23.
Article in English | MEDLINE | ID: mdl-1330372

ABSTRACT

[3H]SCH 23390 bound with high affinity (Kd = 0.6 nM) and in a saturable manner (Bmax = 130 fmol/mg protein) to membrane preparations of the chick optic lobe. Pharmacological experiments, using several dopaminergic ligands, revealed that [3H]SCH 23390 bound stereospecifically to dopaminergic receptors of the D1 type in this tissue. Other experiments revealed that dopamine was able to induce cyclic AMP accumulation in the optic lobe (ED50 = 3 microM), an effect that was blocked by fluphenazine, a potent D1 antagonist (IC50 = 1.8 microM). The developmental profile of tissue dopamine-dependent cyclic AMP accumulation, however, was quite different from the differentiation pattern of [3H]SCH 23390 specific binding sites. While [3H]SCH 23390 binding sites increased 4-fold after the 12th embryonic day (E12), dopamine-dependent cyclic AMP accumulation was maximal in earlier stages, decreasing progressively after E10. In tissues from embryos at E16 or older, no difference was observed between basal and dopamine-stimulated levels of cyclic AMP. These data suggest that D1 receptors are coupled to adenylate cyclase in a limited period of the development of the optic lobe and that D1 receptors not coupled to the enzyme can be a common feature in the CNS.


Subject(s)
Cyclic AMP/metabolism , Dopamine/pharmacology , Fluphenazine/pharmacology , Optic Lobe, Nonmammalian/metabolism , Receptors, Dopamine D1/physiology , Animals , Benzazepines/metabolism , Chick Embryo , Colforsin/pharmacology , Embryonic and Fetal Development , Kinetics , Optic Lobe, Nonmammalian/drug effects , Optic Lobe, Nonmammalian/embryology , Receptors, Dopamine D1/drug effects , Receptors, Dopamine D1/metabolism , Serotonin/pharmacology , Sulpiride/pharmacology
11.
Brain Res ; 530(2): 301-8, 1990 Oct 22.
Article in English | MEDLINE | ID: mdl-2176117

ABSTRACT

[3H]SCH 23390 binds stereospecifically and with high affinity to D1 dopaminergic receptors in the developing chick retina. Autoradiographic experiments revealed that in retinas from 3-day-old chicken and embryos with 12, 14 and 16 days of development, specific labeling of [3H]SCH 23390 was mainly observed over the plexiform layers of the tissue, showing that dopaminergic D1 receptors are localized in retina cell neurites since the initial stages of neurite formation. The total number of [3H]SCH 23390 binding sites increased 5-fold during the differentiation of the retina, while the dopamine-dependent cyclic adenosine monophosphate (AMP) accumulation was significantly decreased. Consequently, the ratio between dopamine-dependent cyclic AMP accumulation and [3H]SCH 23390 binding sites decreased 10-fold as retina differentiated, indicating that a significant portion of D1 receptors in retinas from adult chicken are not effectively coupled to adenylate cyclase molecules.


Subject(s)
Adenylyl Cyclases/metabolism , Neurons/metabolism , Receptors, Dopamine/metabolism , Retina/metabolism , Aging/metabolism , Animals , Autoradiography , Benzazepines/metabolism , Benzazepines/pharmacology , Chick Embryo , Cyclic AMP/metabolism , Dopamine/physiology , In Vitro Techniques , Indicators and Reagents , Membranes/drug effects , Membranes/metabolism , Retina/embryology , Retina/enzymology
12.
J Pharmacol Exp Ther ; 252(2): 810-6, 1990 Feb.
Article in English | MEDLINE | ID: mdl-2138223

ABSTRACT

Mice receiving reserpine (1 mg/kg/day) during 5 days develop behavioral supersensitivity. To study the possible molecular correlates of these adaptive changes we compared binding parameters of D1 and D2 receptors and adenylate cyclase activity in striata from normal and reserpinized mice. Saturation curves using [3H]SCH 23390 showed no changes in maximum binding capacity (Bmax) or Kd of striatal D1 receptors taken from control or 5 days reserpine-treated mice. However, [3H]spiperone saturation curves showed a 31% increase in D2 receptors Bmax with no changes in Kd. Dopamine competition of [3H]SCH 23390 and [3H]spiperone binding in mouse striatum was also performed. Analysis of data by LIGAND showed that dopamine recognizes two subpopulations for D1 and for D2 receptors. The proportion of receptors in the high affinity state (D1high and D2high) were increased in reserpine-treated animals. The addition of 100 microM GTP produced a complete conversion of D1high and D2high receptors into their low-affinity states in striata from control and reserpinized mice. Five days of reserpine treatment increased basal adenylate cyclase activity of mouse striatum in the presence of Mn++ or Mg++ ions. Concentration curves with dopamine, NaF or forskolin revealed shifts to the left and higher maximum responses without changes in EC50 values in striata from reserpinized mice. Thus, a prolonged reserpine treatment produces marked changes in D1 and D2 receptors increasing the proportion of high affinity state subpopulations and the total Bmax of D2 receptors. Also, dopamine function may be enhanced through an increment of the catalytic component of striatal adenylate cyclase.


Subject(s)
Corpus Striatum/drug effects , Receptors, Dopamine/drug effects , Reserpine/pharmacology , Adenylyl Cyclases/analysis , Animals , Benzazepines/metabolism , Colforsin/pharmacology , Magnesium/pharmacology , Male , Manganese/pharmacology , Mice , Receptors, Dopamine D1 , Receptors, Dopamine D2 , Spiperone/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL